top of page
News, Events and Updates
Search
19 hours ago
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
Jan 15
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
Jan 13
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
Jan 6
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 23, 2024
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
Dec 23, 2024
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease
Dec 16, 2024
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024
Dec 9, 2024
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Dec 2, 2024
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024
Sep 3, 2024
Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
Aug 6, 2024
Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
Aug 1, 2024
Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
Jul 30, 2024
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
May 9, 2024
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
Apr 11, 2024
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
Mar 25, 2024
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
Mar 18, 2024
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Feb 26, 2024
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
Feb 1, 2024
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
Jan 24, 2024
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX® 3-71 in Humans
1
2
3
4
5
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
